0:53 - VGK goal called back: A would-be Ivan Barbashev goal is wiped out after a review showed Vegas was guilty of offsides on the score 1:54 - VGK goal: Knights bounce right back from the non ...
In a report released yesterday, Kostas Biliouris from BMO Capital maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report), with a price target of $200.00. Kostas Biliouris has ...
Sarepta Therapeutics unveiled new results from the second part of a clinical trial for its Duchenne muscular dystrophy gene therapy Elevidys … ...
Sarepta (SRPT) announced topline results from Part 2 of EMBARK, a global, randomized, double-blind, placebo-controlled, Phase 3 clinical study of Elevidys, the only approved gene therapy in ...
End of game: Golden Knights struggle to score late in loss to Stars The Vegas Golden Knights had multiple opportunities to tie their game against the Stars late in the third period but were ...
The VGK ETF's recent price increase is driven by strong Q4 earnings expectations for European financial stocks, not by reduced fears of Trump tariffs. Europe faces a complex economic landscape ...
Rare disease specialist Sarepta Therapeutics has joined with Selecta Biosciences in a research pact to develop ways to allow its gene therapies to be re-dosed. Sarepta is developing gene ...
The Vegas Golden Knights (29-15-3) fell to the St. Louis Blues (23-21-4), 5-4, in a shootout on Monday evening at T-Mobile Arena.
SAREPTA, La. -- Working smoke detectors get the credit for a woman surviving a fire in her home Monday night. A woman who lived in a cabin in Sarepta was awakened around 3:40 a.m. to her smoke ...
FINAL— Blues beat VGK 5-4 in a shootout. The Golden Knights didn't have their best on their last road trip as they lost each of the three games. Vegas will keep that trip in the rearview mirror ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback